Zenas BioPharma, Inc. ZBIO
Set alert
As of Nov 2, 1:03 PM ET
- YTD
- -23.24%
- 1 year
- -10.82%
- Open
- 28.47
- Prev close
- 28.39
- Mkt cap
- 1.81B
- Vol
- 183.87K
- Avg vol
- 647.94K
- EPS
- -9.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.15
- High
- 28.81
- Forward P/E
- -6.09
- Beta
- -0.88
- Short ratio
- 17.28
- Inst. own
- 101.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 18, 2026
- 50-d avg
- 29.54
- 200-d avg
- 24.93
- 1y target
- 47.88
News
3 days ago marketbeat.com
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
Zenas BioPharma NASDAQ: ZBIO outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of…
5 days ago seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
1 week ago zacks.com
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
The mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
2 weeks ago globenewswire.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
-
3 weeks ago benzinga.com
Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –– Additional analyses of secondary endpoints showed that significantly fewer patients…
3 weeks ago globenewswire.com
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients…
3 weeks ago globenewswire.com
Zenas BioPharma to Host Virtual R&D Event
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
4 weeks ago seekingalpha.com
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with…
-
1 month ago benzinga.com
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
1 month ago seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
-
1 month ago benzinga.com
Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –– Additional analyses will assess…
1 month ago globenewswire.com
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –
1 month ago globenewswire.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in…
1 month ago seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Zenas BioPharma Registers Resale Of Up To 7M Shares By Selling Stocholder
ZENAS BIOPHARMA, INC.Up to 7,000,000 Shares of Common StockThis prospectus relates to the resale or other disposition from time to time of up to 7,000,000 shares (the "Shares") of our common stock,…
1 month ago defenseworld.net
Analyzing United Therapeutics (NASDAQ:UTHR) and Zenas BioPharma (NASDAQ:ZBIO)
United Therapeutics (NASDAQ: UTHR - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
1 month ago seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
1 month ago globenewswire.com
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in…
1 month ago globenewswire.com
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in…
2 months ago defenseworld.net
Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO
Bank of America Corp DE boosted its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 723.5% during the first quarter, according to its most recent disclosure with the Securities and…
2 months ago globenewswire.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
-
2 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $32
Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $22 to $32.
-
2 months ago benzinga.com
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
-
2 months ago benzinga.com
Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.08) by 63.89 percent. This is a 41.6 percent decrease over losses of…
2 months ago globenewswire.com
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled…
3 months ago defenseworld.net
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare…
3 months ago globenewswire.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the…
4 months ago benzinga.com
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.
5 months ago benzinga.com
Alpha Buying: Insider Conviction in High-Risk Biotech
Alpha Buying: Insider Conviction in High-Risk Biotech
7 months ago benzinga.com
Crude Oil Surges 4%; US Consumer Sentiment Declines In March
U.S. stocks down, NASDAQ drops 1.5% on Friday. Energy shares up, consumer discretionary down. University of Michigan's Consumer Sentiment Index falls.
7 months ago benzinga.com
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
7 months ago benzinga.com
Why Newsmax Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-market gainers include ONCO, VSA, GMEX, IZM, GVH, BATL, U, SGML, & GLND. Losers are SLND, DTCX, TOP, SVRN,…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
9 months ago benzinga.com
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
9 months ago benzinga.com
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
10 months ago benzinga.com
Jefferson Capital, Mobix Labs And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Jefferson Capital, Mobix Labs And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
10 months ago benzinga.com
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
10 months ago benzinga.com
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
10 months ago benzinga.com
US Stocks Higher; Dow Jumps 250 Points
US Stocks Higher; Dow Jumps 250 Points